+Vote!
Market Wire (Free subscription) | yesterday
SOUTH SAN FRANCISCO, CA (MARKET WIRE) Theravance, Inc. (NASDAQ: THRX) announced today that it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) related to the telavancin New Drug Application (NDA) for the treatment of nosocomial pneumonia (NP). Telavancin is a bactericidal, once-daily injectable investigational antibiotic for the treatment of NP caused by Gram-positive...
+Vote!
Health Care Renewal (Free subscription) | yesterday
Recently, we posted about misadventures of the leadership of biotechnology giant Genzyme. Although the company has long priced its drug Cerezyme for the rare Gaucher's disease at a stratospheric level, it did not sufficiently reinvest money in its manufacturing facility for the drug. Deferred maintenance at a production facility running at maximum capacity has apparently lead to two different kinds...
+Vote!
Stock Market Analysis (Free subscription) | yesterday
Below is a list of some of the largest stock gainers and losers so far in pre market for November 27, 2009. Check out my Hot Stocks to Watch page for the latest updates. Pre Market Stock Gainers - 11/27/09 Direxion Daily Emrg Mkts Bear 3X Shares (EDZ) Direxion Daily Small Cap Bear 3X Shares (TZA) UltraShort FTSE/Xinhua China25 Proshares (FXP) Direxion Daily Financial Bear 3X Shares (FAZ) UltraShort...
Explore : International,
International Organisations,
Markets,
Money,
New York Stock Exchange,
PDL BioPharma,
Shanghai Cooperation Organization,
SP 500 Index,
Stock exchange,
Stock markets,
Stocks
3Vote!
Market Wire (Free subscription) | yesterday
NEW DELHI, INDIA (MARKET WIRE) US markets declined but ended off their lows on Tuesday after the Federal Reserve raised its forecast for 2010. Fed minutes indicated that Federal Reserve officials are confident the US economic recovery will be durable, but do not see employment or inflation picking up soon. Today, we, at The Fortune Financial, have asked some of the top analysts worldwide to give us...
3Vote!
Life Science World (Free subscription) | yesterday
[NEWS] ROCHESTER, N.Y., Nov. 27 /PRNewswire-USNewswire/ — Preventing disease is the goal of every health care provider and fortunately every year, new vaccines are being added to assist in disease prevention. But do all vaccines boost immunity for the same period of time? And, if not, when are additional 'booster shots' needed to keep immunity strong? In this month's issue of Pediatrics, the...
+Vote!
Stock Market Analysis (Free subscription) | yesterday
November 27, 2009 - Below is a list of the Top 15 biggest losing stocks today that have decent volume. These stocks are usually going down on bad news. I usually throw these on my watch list and monitor them for a bounce or a potential short trade. Biggest Stock Losers - 11/27/09 1. PDL BioPharma, Inc. (PDLI) - News 2. ING GROUP NV ADS (ING) - News 3. Synta Pharmaceuticals Corp. (SNTA) - No News 4....
+Vote!
PR News Wire (Free subscription) | yesterday
BLOOMINGTON, Minn, Nov. 27 /PRNewswire/ -- ACUO TECHNOLOGIES, developers of high-performance medical image management software, data migration tools and services, is pleased to announce that the United States Patent and Trademark Office has approved a patent application for an "Asset Communication Format within a Computer Network." Acuo Technologies is pleased to add the U.S. patent to its...
+Vote!
CBS 3 (Free subscription) | yesterday
At one Philadelphia workplace this Thanksgiving, the talk is all pig, no turkey. Few people know, but the front line in the fight against the Swine Flu pandemic is inside a plain looking warehouse in Northeast Philadelphia. Home to MedImmune, a division of Astra Zeneca, workers there produce every single dose of swine flu mist vaccine administered across the country.
3Vote!
Click World News (Free subscription) | yesterday
I've posted before about my brother Mark Pescovitz's fine art photography. In his spare time, Mark is a transplant surgeon and medical research scientist. Today, he and his colleagues published a paper in the New England Journal of Medicine about a new way to slow and possibly even stop the progression of type 1 diabetes, also known as juvenile-onset diabetes. The approach uses the drug Rituxan, normally...
3Vote!
Market Wire (Free subscription) | 26/11/2009
OTTAWA, ONTARIO (MARKET WIRE) Health Canada is informing health care professionals and Canadians that routine quality control testing has discovered foreign particles in a small number of vials of five products filled at a Genzyme Corporation facility in Boston. Genzyme has also received customer reports of foreign particles in some vials of these products. The particles observed include non-latex...
+Vote!
Life Science World (Free subscription) | 26/11/2009
[NEWS] Contact: Nicole Giese giese@wi.mit.edu 617-258-6851 Whitehead Institute for Biomedical Research CAMBRIDGE, Mass. (November 26, 2009) - Whitehead researchers have developed a new type of genetic screen for human cells to pinpoint specific genes and proteins used by pathogens, according to their paper in Science. In mos…
3Vote!
Life Science World (Free subscription) | 26/11/2009
[NEWS] Contact: Emil Venere venere@purdue.edu 765-494-4709 Purdue University WEST LAFAYETTE, Ind. - A new generation of ultrasmall transistors and more powerful computer chips using tiny structures called semiconducting nanowires are closer to reality after a key discovery by researchers at IBM, Purdue University and the University of California at Lo…
3Vote!
Life Science World (Free subscription) | 26/11/2009
[NEWS] Contact: Sonia Furtado sonia.furtado@embl.de European Molecular Biology Laboratory EMBL and CRG scientists reveal what a self-sufficient cell can't do without Heidelberg, 27 November 2009 - What are the bare essentials of life, the indispensable ingredients required to produce a cell that can survive on its own? Can we…
3Vote!
The Earth Times Online Newspaper (Free subscription) | 26/11/2009
MECHELEN, BELGIUM -- 11/26/09 -- Mechelen, Belgium; 26 November 2009 - Galapagos NV (Euronext: GLPG) announces that its antibody therapeutics program with MorphoSys and SARM program have been awarded funding by the French gove..
3Vote!
The Dangerous Economist (Free subscription) | 26/11/2009
These legislators make lots of speeches and ask questions at congressional hearings. That is part of their job and maybe they like doing that sort of thing (which might explain why they ran for office in the first place). So you might assume that the taxpayers are paying them to talk. But maybe not. The New York Times had an article recently called In House, Many Spoke With One Voice: Lobbyists’...
Videos